Q

& u including mortality, after stenting using clopidogrel instead of ticlopidine. Circulation 2000;102(suppl II):565.

63. Bhatt DL, Chew DP, Hirsch AT, et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001;103:363-368.

64. UK Perspective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications inpatients with type 2 diabetes (UKPDS). Lancet 1998;352:837-853.

65. Al-Rashdan IR, Rankin JM, Elliott TG, et al. Glycemic control and major adverse cardiac events after PTCA in patients with diabetes mellitus. J Am Coll Cardiol 1999;33:97A.

66. Yumoto K, Kato K, Doi H, et al. The influence of diabetic control on restenosis after coronary stenting. Circulation 2000;102(suppl II):730.

67. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999;33:119-124.

68. Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol 1998;31:950-956.

69. Takagi T, Akasaka T, Kaji S, et al. Increased intimal hyperplasia after coronary stent implantation in patients with hyperinsulinemia: a serial intravascular ultrasound study. Circulation 1998;98(suppl 1):229.

70. Takagi T, Yoshida K, Akasaka T, et al. Triglitazone reduces intimal hyperplasia after coronary stent implantation in patients with type 2 diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 1999;33(suppl A):33A.

71. Weintraub WS, Boccuzzi SJ, Klein JL. Lack of effect of Lovastatin on Restenoses after coronary angioplasty N Engl J Med 1994;331:1331-1336.

72. Treasure CB, Klein JL, Weintraub WS. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487.

73. Haffner SM. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care 1997;20:469-471.

74. Goldberg RB, Mellies MJ, Sacks FM. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Circulation 1998;98:2513 -2519.

75. The Long-Term Intervention With Pravastatin In Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl

J Med 1998;339:1349-1357. -o

76. Elsner M, Walter DH, Auch-Schwelk, et al. Statin therapy in diabetic patients is associated with reduced clinical event rates and attenuated neointimal proliferation after coronary stenting. Circulation 1999;100(suppl I):365. -S,

77. Campeau L, Enjalbert M, Lesperance J, et al. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation: a study 10 years after aortocoronary bypass surgery. N Engl J Med 1984;311:1329-1332. |

Supplements For Diabetics

Supplements For Diabetics

All you need is a proper diet of fresh fruits and vegetables and get plenty of exercise and you'll be fine. Ever heard those words from your doctor? If that's all heshe recommends then you're missing out an important ingredient for health that he's not telling you. Fact is that you can adhere to the strictest diet, watch everything you eat and get the exercise of amarathon runner and still come down with diabetic complications. Diet, exercise and standard drug treatments simply aren't enough to help keep your diabetes under control.

Get My Free Ebook


Post a comment